AbSano Develops
Novel Antibodies

For innovative diagnostic tools as well as therapeutic purposes

AbSano identifies and develops novel monoclonal antibodies for therapeutic applications as well as innovative diagnostic tools using our in-house technology within our state-of-the-art antibody discovery pipeline. Opportunities are available for in-licensing of individual programs and phage display libraries (naive and patent derived libraries).

This Is What We Do

Current projects involve the identification and optimization of antibodies targeting SARS-CoV-2 as well as key players in autoimmune diseases and various cancer types. As these selected targets have important roles during the course of various diseases, development of specific antibodies will open up possibilities for diagnostic and therapeutic applications. For instance, depending on the target of interest, these antibodies can be used to interfere with endogenous protein function or to guide a certain compound to the right cell population.

Our Methods


The broad variety of techniques and knowledge available in-house, enables AbSano to develop antibodies from start to finish. This process includes the isolation and identification of antibody sequences, selection of the most specific antibodies, tools and knowledge for efficient antibody humanization, and optimized protocols for the production of antibodies. During antibody development, AbSano utilizes a diverse set of approaches, including hybridoma culture as well as phage display from various species and with different antibody formats, to increase the variability within the set of lead antibodies. Thereby, we ensure the highest chances of success during subsequent validation and functional assays.